Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$158.05$261.00
1-Month Range
Month up 10.5%
$228.90$254.87
Daily Price Range
Day down -0.1%
$249.44$253.24
Volume
vs 1M avg
2072401M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$37.4B
Short % of Float—
Employees—
Sales$9,891M
Shares Outstanding147,820,223
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.biib.com
Biogen Inc — Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatm….· via yahoo
Warnings
1 signal
Live
- ROE below 5% (1.9%)
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
73
Growth
85
Quality
37
Sentiment
95
Insider Sent.
0
Piotroski F
6
Altman Z
3.7
Consensus rating unavailable — no analyst coverage on file for BIIB.
Price targets unavailable — no 12-month targets on file for BIIB.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on BIIB, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 1 warnings surfacedNov 11, 2026, 6:08 PM UTC